The U.S. Food and Drug Administration (FDA) announced its approval of a new drug called Olumiant (baricitinib), a once-daily oral tablet that treats adult patients with severe alopecia areata.
On Monday, the FDA released a statement announcing its”first systemic treatment” which treats the entire body for those battling the autoimmune disorder affecting more than 6 million Americans. With Alopecia areata, the body attacks its hair follicles, causing clumps of hair loss.